Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Disclosures

CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.

Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.

 

Recent Contributions to PracticeUpdate:

  1. Dexamethasone Favored for Castration-Resistant Prostate Cancer
  2. Increased Disease Recurrence After Prostatectomy in Black Patients With Low-Grade Prostate Cancer
  3. What Is the Value of Lower Testosterone in ADT-Treated Patients?
  4. Nadir Testosterone Within First Year of ADT Predicts Time to Castration-Resistant Progression
  5. Low Testosterone in First Year of ADT Linked to Improved Outcomes
  6. Targeting the Androgen Receptor Confers In Vivo Cross-Resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-Resistant Prostate Cancer
  7. Survival With Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era"
  8. Leuprolide Plus Abiraterone More Effective in Prostate Cancer Than Abiraterone Alone
  9. PSA Helps Determine Whether to Treat or Watch After Radical Prostatectomy
  10. Clinical Relevance of AR-V7 in Castrate-Resistant Prostate Cancer

Most Read This Week

Recently Updated